Malignant Peripheral Nerve Sheath Tumor
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Malignant Peripheral Nerve Sheath Tumor

What is the definition of Malignant Peripheral Nerve Sheath Tumor?
A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.
What are the alternative names for Malignant Peripheral Nerve Sheath Tumor?
  • Malignant peripheral nerve sheath tumor
  • MPNST
  • Malignant neurilemmoma
  • Malignant neurofibroma
  • Malignant schwannoma
  • Neurofibrosarcoma
  • Neurogenic sarcoma
Who are the top Malignant Peripheral Nerve Sheath Tumor Local Doctors?
Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatrics | Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatrics | Oncology
Referral may be required

Johns Hopkins Children's Center

Baltimore, MD 
Languages Spoken:
English
Accepting New Patients

Christine Pratilas is a Pediatrics specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Pratilas is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Osteotomy. Dr. Pratilas is board certified in American Board Of Pediatrics. Dr. Pratilas is currently accepting new patients.

Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatric Hematology Oncology
Referral may be required

Telehealth Video Visit

111 Michigan Avenue Northwest, Childrens National Telemedicine, 
Washington, DC 
Languages Spoken:
English

Aerang Kim is a Pediatric Hematologist Oncology provider practicing medicine in Washington, Washington, D.c.. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma. Dr. Kim is board certified in Pediatrics: American Board Of Pediatrics, 2004 and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Malignant Peripheral Nerve Sheath Tumor
Elite in Malignant Peripheral Nerve Sheath Tumor
Referral may be required

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Christian Meyer is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Osteosarcoma, and Salpingo-Oophorectomy. Dr. Meyer is board certified in American Board Of Internal Medicine. Dr. Meyer is currently accepting new patients.

What are the latest Malignant Peripheral Nerve Sheath Tumor Clinical Trials?
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Summary: This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Match to trials
Find the right clinical trials for you in under a minute
Get started
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center